A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist (PF-04634817) With That Of Ranibizumab In Adult Subjects With Diabetic Macular Edema
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Sofia, Bulgaria, 1612
- MC Comac Medical
-
-
-
-
-
Hradec Kralove, Czech Republic, 500 05
- Fakultní nemocnice Hradec Králové, Ocni klinika
-
Hradec Kralove, Czech Republic, 50005
- Fakultní nemocnice Hradec Králové, Nemocnicni lekarna
-
Ostrava - Poruba, Czech Republic, 70852
- Fakultni nemocnice Ostrava, lekarna
-
Ostrava - Poruba, Czech Republic, 70852
- Fakultni Nemocnice Ostrava, Oční Klinika
-
Praha 10, Czech Republic, 10034
- Fakultni nemocnice Kralovske Vinohrady, Oftalmologicka klinika
-
Praha 10, Czech Republic, 10034
- Fakultni nemocnice Kralovske Vinohrady, Ustavni lekarna
-
-
-
-
-
Berlin, Germany, 12200
- Charite - Universitaetsmedizin Berlin, Campus Benjamin Franklin
-
Goettingen, Germany, 37075
- Universitaetsmedizin Goettingen
-
Mainz, Germany, 55131
- Universitatsmedizin Mainz
-
Muenster, Germany, 48145
- Augenärzte am St. Franziskus-Hospital
-
Muenster, Germany, 48159
- Universitaetsklinikum Muenster
-
Sulzbach, Saar, Germany, 66280
- Knappschaftsklinikum GmbH
-
Tubingen, Germany, 72076
- Universitatsklinikum Tubingen
-
-
Bavaria
-
Regensburg, Bavaria, Germany, 93053
- Universitätsklinikum Regensburg
-
-
-
-
-
Budapest, Hungary, 1133
- Budapest Retina Associates Kft.
-
Budapest, Hungary, 1083
- Semmelweis Egyetem, Szemeszeti Klinika
-
Budapest, Hungary, 1106
- Bajcsy-Zsilinszky Korhaz, Szemeszet
-
Debrecen, Hungary, 4032
- Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, Szemklinika
-
Pecs, Hungary, 7621
- Ganglion Orvosi Központ
-
Veszprem, Hungary, 8200
- Csolnoky Ferenc Korhaz, Szemeszeti Osztaly
-
-
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Organization, Hadassah Medical Center, Ein Karem
-
Kfar Saba, Israel, 44281
- Meir Medical Center
-
Petah Tikva, Israel, 49100
- Rabin Medical Center, Beilinson Hospital
-
Rehovot, Israel, 76100
- Kaplan Medical Center
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Chisinau, Moldova, Republic of, MD-2025
- Spitalul Clinic Republican
-
-
-
-
-
Wroclaw, Poland, 50-367
- Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza Radeckiego We Wrocławiu, Klinika Okulistyki
-
-
-
-
-
Bucuresti, Romania, 010719
- Med Life SA, Sectia Oftalmologie
-
Bucuresti, Romania, 020475
- Institutul National de Diabet, Nutritie si Boli Metabolice "N.C.Paulescu"
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85014
- Retinal Consultants of Arizona
-
Phoenix, Arizona, United States, 85014
- Retina Research Institute, LLC
-
Phoenix, Arizona, United States, 85018
- Sunny View Medical Center
-
Phoenix, Arizona, United States, 85027
- Premier Research Group Limited
-
Tucson, Arizona, United States, 85704
- Retina Centers, P.C.
-
-
California
-
Arcadia, California, United States, 91007
- Retina Institute of California
-
Beverly Hills, California, United States, 90211
- Retina Vitreous Associates Medical Group
-
Campbell, California, United States, 95008
- Retinal Diagnostic Center
-
Laguna Hills, California, United States, 92653
- Retina Associates of Orange County
-
Palm Desert, California, United States, 92211
- Southern California Desert Retina Consultants
-
Whittier, California, United States, 90603
- American Institute of Research (Administrative Only)
-
-
Connecticut
-
New London, Connecticut, United States, 06320
- New England Retina Associates
-
-
Florida
-
Miami, Florida, United States, 33136
- Bascom Palmer Eye Institute
-
Plantation, Florida, United States, 33324
- Fort Lauderdale Eye Institute
-
Winter Haven, Florida, United States, 33880
- Center for Retina and Macular Disease
-
-
Georgia
-
Augusta, Georgia, United States, 30909
- Southeast Retina Center, PC
-
-
Indiana
-
Indianapolis, Indiana, United States, 46290
- Midwest Eye Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Michigan
-
Jackson, Michigan, United States, 49202
- TLC Eyecare & Laser Center
-
Royal Oak, Michigan, United States, 48073
- Wm Beaumont Medical Office Building
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28210
- Charlotte Eye Ear Nose and Throat Associates PA
-
-
Ohio
-
Cleveland, Ohio, United States, 44122
- Retina Associates of Cleveland, Inc.
-
Youngstown, Ohio, United States, 44505
- Retina Associates of Cleveland
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Dean McGee Eye Institute
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma -OU Physicians
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Retina Vitreous Consultants
-
West Mifflin, Pennsylvania, United States, 15122
- Associates in Ophthalmology Ltd
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57701
- Black Hills Regional Eye Institute
-
-
Texas
-
Austin, Texas, United States, 78705
- Retina Research Center
-
Austin, Texas, United States, 78705
- Brain B.Berger,MD,PA
-
Houston, Texas, United States, 77030
- Retina Consultants of Houston, PA
-
San Antonio, Texas, United States, 78240
- Medical Center Ophthalmology Associates
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- Rocky Mountain Retina Consultants
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with Diabetes Mellitus (Type 1 or Type 2) Showing Diabetic Macular Edema in the Eye
- Reduced visual acuity resulting from retinal thickening
- Female subjects of non-childbearing potential ≥18 years and male subjects greater than or equal to 18 years. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active.
Female subjects who are not of childbearing potential must meet at least one of the following criteria:
- Have undergone a documented hysterectomy and/or bilateral oophorectomy;
- Have medically confirmed ovarian failure; or
- Achieved post-menopausal status, defined as: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; and have a serum follicle stimulating hormone (FSH) level within the laboratory's reference range for postmenopausal females.
Exclusion Criteria:
- Severe Impaired Renal Function
- Any intraocular condition or previous surgery in either eye that would likely require medical or surgical intervention during the study duration or if allowed to progress untreated for the 16 weeks of study duration, would likely contribute to a reduction in visual acuity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Arm 1
Intravitreal administration of ranibizumab (either 0.3 or 0.5 mg, given monthly, as detailed in the prescribing information and label content approved for the country governing the study site) plus an oral placebo.
|
Intravitreal Injection supplied as:
Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817. Dose is 4 tablets each day for 12 weeks |
|
Experimental: Arm 2
Oral PF-04634817 200 mg, once daily plus a masked sham therapy (given monthly).
|
Four 50mg tablets PF-04634817 once a day for 12 weeks.
Empty, needle-less syringe is used by the unmasked team once a month.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Letter Change From Baseline at Week 12 in Best Corrected Visual Acuity (BCVA)
Time Frame: Baseline (Day 0) and Week 12
|
Refraction and visual acuity were assessed through the BCVA obtained using the retro illuminated early treatment diabetic retinopathy study (ETDRS) charts.
Distance visual acuity was expressed as an ETDRS score (number of letters correctly read).
|
Baseline (Day 0) and Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of Subjects Gaining 15 ETDRS Letters in BCVA From Baseline at Week 12
Time Frame: Baseline (Day 0) and Week 12
|
Refraction and visual acuity were assessed through the BCVA obtained using the retro illuminated ETDRS charts.
Distance visual acuity was expressed as an ETDRS score (number of letters correctly read).
|
Baseline (Day 0) and Week 12
|
|
Mean Change From Baseline in Central Subfield Retinal Thickness in the Study Eye at Week 12
Time Frame: Baseline (Day 0) and Week 12
|
A central reading center was used for the evaluation.
A photographer or technician pre certified ("study certified") by the Central Reading Center ought to perform all optical coherence tomography (OCT) imaging.
Use of a Spectralis or Cirrus OCT was acceptable.
|
Baseline (Day 0) and Week 12
|
|
Mean Change From Baseline in The Area of Fluorescein Leakage in the Study Eye at Week 12
Time Frame: Baseline (Day 0) and Week 12
|
Fluorescein Angiography (FA) using certified digital systems was taken by a photographer who had been pre-certified ("study-certified") by the Central Reading Center.
They were evaluated by the Central Reading Center.
|
Baseline (Day 0) and Week 12
|
|
Mean Change From Baseline in Steps of Diabetic Retinopathy Step (ETDRS Severity Scale) in the Study Eye at Week 12
Time Frame: Baseline (Day 0) and Week 12
|
Stereo color fundus photographs using certified digital systems were taken by a photographer who had been pre-certified ("study certified") by the Central Reading Center.
They were evaluated by the Central Reading Center.
|
Baseline (Day 0) and Week 12
|
|
Plasma Concentration of PF-04634817 up to Week 12
Time Frame: Week 0, Week 4, Week 8, and Week 12
|
Week 0, Week 4, Week 8, and Week 12
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
Time Frame: Week 0 to Week 16
|
An AE was any untoward medical occurrence without regard to causality in a participant who received study drug.
A SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
|
Week 0 to Week 16
|
|
Number of Participants With Potentially Clinically Important Post-Baseline Vital Signs
Time Frame: Week -5 to Week 16
|
Number of participants who met the categorical summary of post-baseline criteria at any time point, defined as: supine pulse rate <40 beats per minute (bpm) or >120 bpm; supine systolic blood pressure (SBP) ≥30 millimeters of mercury (mmHg) change from baseline in same posture; supine diastolic BP (DBP) ≥20 mmHg change from baseline in same posture; supine SBP <90 mmHg; supine DBP <50 mmHg.
|
Week -5 to Week 16
|
|
Number of Participants With Laboratory Abnormalities
Time Frame: Week -5 to Week 16
|
The following laboratory parameters were analyzed for abnormalities at any time point: hematology (hemoglobin, hematocrit, red blood cell count (RBC), white blood cell count (WBC) with differential, and platelet count); blood chemistry (sodium, potassium, chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, albumin, calcium, total, direct and indirect bilirubin, gamma glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactic dehydrogenase (LDH), alkaline phosphatase, creatine phosphokinase (CPK), uric acid, amylase and lipase); follicle-stimulating hormone (FSH) (Weeks -5 to 0 only, for postmenopausal women who have been amenorrheic for at least 12 consecutive months prior to screening visit).
|
Week -5 to Week 16
|
|
Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Findings
Time Frame: Week -5 to Week 16
|
ECG parameters included PR interval, QRS interval, and corrected QT interval using Fridericia's formula (QTcF).
Criteria for ECG changes meeting potential clinical concern included: PR interval greater than or equal to (>=)300 milliseconds (msec) or >=25% increase when baseline is greater than (>)200 msec and >=50% increase when baseline is less than or equal to (≤)200 msec; QRS interval >=200 msec or >=25% increase when baseline is greater than (>)200 msec and >=50% increase when baseline is less than or equal to (≤)200 msec; QT interval >=500 msec; and QTcF >=450 msec or >=30 msec increase.
The number of participants with potentially clinically significant ECG findings at any visit were reported.
|
Week -5 to Week 16
|
|
Number of Participants With Changes in the Anterior Segment of the Study Eye at Week 12
Time Frame: Week -5 to Week 16
|
The anterior biomicroscopy exam was done undilated in order to assess whether there was any anterior segment inflammation caused either by ranibizumab or PF-04634817.
|
Week -5 to Week 16
|
|
Maximum Increase of Intraocular Pressure (IOP) From Baseline in Study Eye
Time Frame: Week -5 to Week 16
|
IOP was measured using Goldmann applanation tonometry.
To maintain consistency, it was recommended that the same examiner ought to measure IOP with the same tonometer at each visit for a given subject.
Intraocular pressure ought to be measured in the study eye approximately 30 minutes after intravitreal injection or masked sham therapy (performed by unmasked study team member).
|
Week -5 to Week 16
|
|
Number of Participants With Change in Ophthalmoscopy Examination Results in Study Eye After Administration of Ranibizumab or Masked Sham Therapy at Week 8
Time Frame: Week -5 to Week 16
|
Ophthalmoscopy ought to be performed after pupillary dilation to examine the vitreous body, optic nerve head, macular and peripheral retina.
All findings, including the presence or absence of vitreous inflammation, ought to be documented.
All post-dose ophthalmoscopy assessments ought to be made immediately following the administration of ranibizumab or masked sham therapy.
|
Week -5 to Week 16
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- B1261009
- 2013-003147-27 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.